PCN162 A COST MINIMISATION ANALYSIS OF 24-MONTH FIXED DURATION OF VENETOCLAX PLUS RITUXIMAB VERSUS IBRUTINIB FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN PORTUGAL
Abstract
Authors
L. Silva Miguel A.T. Paquete J.M. Pereira I. Ramos J. Alarcão M. Borges